Endogenous 28-amino-acid thymic peptide; generic medicine name thymalfasin
PRODUCT PROFILE
Thymosin Alpha-1
£69.00
Thymosin Alpha-1 is endogenous 28-amino-acid thymic peptide; generic medicine name thymalfasin. Researchers examine it in relation to dendritic-cell, t-cell and innate immune-response regulation.
Why it is distinct
An immune-response modulator with human clinical literature, distinct from LL-37’s direct antimicrobial activity.
- Evidence stageEstablished
- AvailabilityUnavailable
- Batch recordOpen COA
- DispatchConfirmed at checkout
Out of stock
Ask about availabilitySUGGESTED ADD-ONS
Useful additions, clearly shown.
Suggestions are organised by vial format and catalogue context. They are not combined-use guidance or personal-use advice.
-
Specification review
Bacteriostatic Water
Price range: £4.49 through £8.9910 mL | 3 mLBatch file pendingA laboratory supply with two volume variants, not a peptide or biologically active comparison material.
Available · select size for stockAdd to basket This product has multiple variants. The options may be chosen on the product page -
Preclinical
BPC-157
£32.99Batch COA availableBPC-157 is mainly discussed around stomach and local tissue-repair models. TB-500 is instead studied for actin, cell movement…
Available · 30 in stockAdd to basket -
Preclinical
TB-500
£32.99Batch COA availableTB-500 is discussed as a fragment-like repair material, while thymosin beta-4 is the full natural protein and BPC-157…
Available · 30 in stockAdd to basket
PRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
Thymosin Alpha-1 is endogenous 28-amino-acid thymic peptide; generic medicine name thymalfasin. Researchers examine it in relation to dendritic-cell, t-cell and innate immune-response regulation.
Research focus+
Researchers study how it helps immune cells coordinate responses to infection and other challenges. Authorised medical versions exist in some countries, but availability and approved uses vary.
How the mechanism differs+
Modulates Toll-like-receptor-linked and adaptive immune signalling rather than directly killing microbes.
Evidence and limitations+
Human trials exist across immune and infectious-disease settings; authorised status is country- and indication-specific.
Testing and batch documentation+
Verified batch documents are available for review.
RESEARCH PROFILE
Understand the distinction.
Researchers study how it helps immune cells coordinate responses to infection and other challenges. Authorised medical versions exist in some countries, but availability and approved uses vary.
Modulates Toll-like-receptor-linked and adaptive immune signalling rather than directly killing microbes.
An immune-response modulator with human clinical literature, distinct from LL-37’s direct antimicrobial activity.
Human trials exist across immune and infectious-disease settings; authorised status is country- and indication-specific.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Early human evidence
LL-37
£59.005 mgBatch COA availableDirect antimicrobial membrane activity separates it from immune regulators such as KPV or thymosin alpha-1.
UnavailableAsk about availability -
Preclinical
KPV
Price range: £27.47 through £29.9910 mgBatch COA availableA minimal anti-inflammatory alpha-MSH fragment rather than an antimicrobial peptide such as LL-37.
Available · select size for stockAdd to basket This product has multiple variants. The options may be chosen on the product page